Author + information
- Katrien Blanchart, MDa,∗ (, )
- Eric Saloux, MDa,
- Remi Sabatier, MD, PhDa,
- Vincent Roule, MDa,b and
- Farzin Beygui, MD, PhDa,b,c
- aDepartment of Cardiology, Caen University Hospital, Caen, France
- bResearch Group 4650, Normandy University, Caen, France
- cACTION Study Group, Pitié-Salpêtrière University Hospital, Paris, France
- ↵∗Address for correspondence:
Dr. Katrien Blanchart, Department of Cardiology, Caen University Hospital, Avenue Côte de Nacre, 14033 Caen, France.
Heart failure (HF) is an increasing pandemic affecting more than 26 million people worldwide. Despite growing therapeutic options, the outlook of patients with HF remains particularly poor with high mortality and rehospitalization rates. When HF remains uncontrolled despite optimal medical therapy, mechanical circulatory devices or heart transplantation must be considered. Unfortunately, these therapeutic options are limited. This case explains how consecutive minimally invasive treatment allowed stabilization of end-stage HF thereby avoiding heart transplantation or mechanical assist devices. (Level of Difficulty: Intermediate.)
- cardiac transplantation
- heart failure
- heart team
- percutaneous mitral valve repair
- transcatheter aortic valve replacement
Dr. Beygui has received institutional research grants from Medtronic, Biosensor, Boston Scientific, Acist, and St. Jude Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received April 4, 2019.
- Revision received May 2, 2019.
- Accepted May 9, 2019.
- 2019 The Authors